RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20 AUG 90

File: 120396_sep96_decls54_0006.txt
Page: 0006
Total Pages: 16

Subject: RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20 AUG 90          

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003201

Folder Title: OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT                            

Document Number:          1

Folder SEQ  #:         45







          effective. Rarely, penicillin-resistant strains have been recovered from fatal

          human cases.

                V PROPHYLAXIS

                PRE-EXPOSURE

                VACCINE
                An alum-precipitated preparation of purified Bacillus anthracis protective
          antigen (PA) has been shown to be effective in preventing or significantly
          reducing the incidence of inhalation anthrax. Studies in rhesus monkeys
          indicate that good protection is afforded after 2 doses (14-16 days apart) for
          periods up to a year. Limited human data suggests that, after completion of the
          entire 6-dose primary series (0,2,4 weeks, then 6,12,18 months), protection
          against both cutaneous and inhalation anthrax is afforded. There is likely
          protection after 2 doses in humans as well, but there is too little information to
          draw firm conclusions. As with all vaccines, the degree of protection is
          proportional to the challenge dose; vaccine-induced protection is undoubtedly
          overwhelmed by extremely high spore challenge.
                The vaccine is a commercially-available, licensed product manufactured
          by the Michigan Department of Public Health. Limited quantities of vaccine
          are currently in-stock, while additional amounts will be available for
          distribution by 1 October 1990. Given projected availabilities, we recommend
          administration of 2 doses, 0.5 ml subcutaneously, on days 0 and 14.
          Contraindications for use are sensitivity to vaccine components (formalin, alum,
          benzethonium chloride) and/or history of clinical anthrax. Reactogenicity is
          mild to moderate: up to 6% of recipients will experience mild discomfort at the
          inoculation site for up to 72 hours (tenderness, erythema, edema, pruritis),
          while a smaller proportion ( < 1 %) will experience more severe local reactions
6      DRAFT

Document 16 f:/Week-36/BX003201/OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT/response to the biological warfare bw threat 20 :11229616342212
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = OPERATION DESERT SHIELD RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT
Folder Seq # = 45
Subject = RESPONSE TO THE BIOLOGICAL WARFARE BW THREAT 20
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 22-NOV-1996